News
ISA Pharmaceuticals And Cancer Focus Fund Announce $5 Million Investment To Support First- In-Human Trial Of ISA’s Novel Immunotherapy ISA103 In Uveal Melanoma
PR Newswire | 01/04/23
Drug Could Bring Immunotherapy To Millions Of Cancer Patients
No Camels | 12/29/22
Israeli Biotech Company Begins Trial For Cancer Immuno-Oncology Solution
The Jerusalem Post | 11/30/22
MD Anderson VC Arm Joins $25M Funding Round For Cancer Drug Company
Becker’s Healthcare | 11/30/22
Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
PR Newswire | 11/30/22
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy
PR Newswire | 03/07/22
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
PR Newswire | 02/17/2022
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers
PR Newswire | 05/26/2021
Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson
Mereo BioPharma | 04/30/21
MD Anderson Brings Underdogs into the Fight Against Cancer with Focus Fund
BioSpace | 10/21/20
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials
PR Newswire | 10/20/20